Henan Lingrui Pharmaceutical マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Wei Xiong

最高経営責任者

CN¥1.8m

報酬総額

CEO給与比率	n/a
CEO在任期間	1.5yrs
CEOの所有権	0.6%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

CEO（最高経営責任者

Wei Xiong (39 yo)

1.5yrs

在職期間

CN¥1,804,900

報酬

Mr. Wei Xiong serves as General Manager and Chairman at Henan Lingrui Pharmaceutical Co. Ltd. since May 18, 2023 and served as its Managing Director.

Henan Lingrui Pharmaceutical マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Henan Lingrui Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.27 in 3Q 2023)

New minor risk - Share price stability

Henan Lingrui Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorates as stock falls 20%

Second quarter 2024 earnings released: EPS: CN¥0.39 (vs CN¥0.30 in 2Q 2023)

Henan Lingrui Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 13, 2024

Dividend of CN¥0.80 announced

Full year 2023 earnings released: EPS: CN¥1.01 (vs CN¥0.84 in FY 2022)

Henan Lingrui Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Henan Lingrui Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Henan Lingrui Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.24 in 3Q 2022)

Henan Lingrui Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.25 in 2Q 2022)

Now 22% undervalued

First quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.24 in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.20 in 3Q 2021)

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.22 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.17 in 1Q 2021)

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.18 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.14 in 1Q 2020)

New 90-day low: CN¥7.91

New 90-day low: CN¥8.09

New 90-day low: CN¥9.11

New 90-day low: CN¥9.28

Third quarter earnings released

New 90-day low: CN¥9.88

Earnings released

Henan Lingrui Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020

CEO（最高経営責任者

在職期間

報酬

マネジメント基準チェック /14